Calithera Biosciences, Inc. (CALA) Reaches $8.00 After 7.00% Up Move; Colony Northstar (CLNS) Shorts Up By 16.56%

February 21, 2018 - By Michael Collier

Colony Northstar Inc (NYSE:CLNS) had an increase of 16.56% in short interest. CLNS’s SI was 10.77M shares in February as released by FINRA. Its up 16.56% from 9.24M shares previously. With 8.47M avg volume, 1 days are for Colony Northstar Inc (NYSE:CLNS)’s short sellers to cover CLNS’s short positions. The SI to Colony Northstar Inc’s float is 2.24%. The stock decreased 0.55% or $0.045 during the last trading session, reaching $8.205. About 970,371 shares traded. Colony NorthStar, Inc. (NYSE:CLNS) has risen 25.53% since February 21, 2017 and is uptrending. It has outperformed by 8.83% the S&P500.

The stock of Calithera Biosciences, Inc. (NASDAQ:CALA) is a huge mover today! The stock increased 3.90% or $0.3 during the last trading session, reaching $8. About 219,344 shares traded. Calithera Biosciences, Inc. (NASDAQ:CALA) has risen 278.82% since February 21, 2017 and is uptrending. It has outperformed by 262.12% the S&P500.The move comes after 7 months positive chart setup for the $283.81 million company. It was reported on Feb, 21 by Barchart.com. We have $8.56 PT which if reached, will make NASDAQ:CALA worth $19.87M more.

Among 5 analysts covering Calithera Biosciences (NASDAQ:CALA), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Calithera Biosciences had 10 analyst reports since July 24, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Tuesday, January 24 by Citigroup. The rating was initiated by H.C. Wainwright with “Buy” on Thursday, January 5. Citigroup initiated the stock with “Sell” rating in Tuesday, October 25 report. The stock of Calithera Biosciences, Inc. (NASDAQ:CALA) has “Buy” rating given on Friday, February 16 by Citigroup. The rating was initiated by Citigroup on Friday, July 24 with “Buy”. The rating was maintained by JMP Securities with “Market Outperform” on Wednesday, March 9. The firm has “Buy” rating given on Tuesday, March 28 by H.C. Wainwright. On Monday, June 12 the stock rating was maintained by H.C. Wainwright with “Buy”.

Investors sentiment decreased to 1.22 in Q3 2017. Its down 2.03, from 3.25 in 2017Q2. It is negative, as 16 investors sold Calithera Biosciences, Inc. shares while 21 reduced holdings. 14 funds opened positions while 31 raised stakes. 25.24 million shares or 49.47% less from 49.95 million shares in 2017Q2 were reported. Invesco Limited reported 152,798 shares. Edge Wealth Management Ltd Llc has 0.01% invested in Calithera Biosciences, Inc. (NASDAQ:CALA) for 1,800 shares. Iconiq Cap Limited Liability Company owns 23,222 shares. Strs Ohio owns 3,600 shares. Victory Cap Mgmt holds 97,280 shares or 0% of its portfolio. Macquarie Gp Limited reported 4,600 shares. 3,159 were reported by Royal Comml Bank Of Canada. Lord Abbett Limited Liability Com holds 0.03% or 630,261 shares in its portfolio. Fred Alger Mgmt accumulated 10,000 shares. 1.10 million were accumulated by Vanguard Gp. Amer Century Inc holds 0.01% or 424,752 shares. 52 are owned by Meeder Asset. Dupont Capital accumulated 0.01% or 16,394 shares. Tiaa Cref Inv Mngmt Ltd Liability Corporation has invested 0% in Calithera Biosciences, Inc. (NASDAQ:CALA). Voya Investment Management Ltd reported 0% in Calithera Biosciences, Inc. (NASDAQ:CALA).

Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company has market cap of $283.81 million. The Company’s lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase Ib/2 clinical trials for the treatment of solid tumors. It currently has negative earnings. The firm has a license agreement with Mars, Inc. to develop and commercialize SymbioscienceÂ’s portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors.

Analysts await Calithera Biosciences, Inc. (NASDAQ:CALA) to report earnings on March, 15. They expect $-0.24 EPS, up 46.67% or $0.21 from last year’s $-0.45 per share. After $-0.17 actual EPS reported by Calithera Biosciences, Inc. for the previous quarter, Wall Street now forecasts 41.18% negative EPS growth.

Among 2 analysts covering Colony NorthStar (NYSE:CLNS), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Colony NorthStar had 2 analyst reports since March 31, 2017 according to SRatingsIntel. Wedbush maintained it with “Outperform” rating and $17.25 target in Friday, April 21 report. The firm earned “Mkt Perform” rating on Friday, March 31 by JMP Securities.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Michael Collier

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: